A cost-effective technique for experimental coronary artery bypass

McCarthy, Patrick M.; Schaff, Hartzell V.

doi:10.1016/s0022-5223(19)35293-6

Cited by 11 publications

(1 citation statement)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One week after the initiation of nicotine patch therapy, reversed saphenous veins were placed as CABG from the left subclavian artery to the circumflex coronary artery without cardiopulmonary bypass, as previously described (32). The bypassed segment of coronary artery was ligated so that blood flow to the distal coronary artery was graft dependent.…”

Section: Animalsmentioning

confidence: 99%

Effects of transdermal nicotine treatment on structure and function of coronary artery bypass grafts

Clouse

Yamaguchi

Phillips

et al. 2000

Journal of Applied Physiology

Self Cite

View full text Add to dashboard Cite

Smoking is a major risk factor for failure of coronary artery bypass grafts (CABG). Experiments were designed to determine effects of transdermal nicotine, independent of smoking, on structure and function of CABG. Saphenous veins were placed as CABG in untreated dogs (control) or in dogs treated with transdermal nicotine (one 11-mg or two 22-mg patches/day) for 5 wk. Serum nicotine and plasma nitric oxide were measured. Grafts were removed and prepared for organ chamber studies and histology. Serum nicotine averaged 12.1 and 118.7 ng/ml in the 11 mg/day and 44 mg/day groups, respectively. Plasma nitric oxide was higher in dogs treated with 11 mg/day doses compared with controls. In organ chamber studies, endothelium-dependent relaxations to thrombin and A-23187 and endothelium-independent relaxations to nitric oxide were greatest in grafts from dogs treated with 11 mg/day doses. Intimal thickness of the grafts were similar among groups. However, staining for bone sialoprotein was increased in the media of grafts from the 11 mg/day treatment group. These data suggest that transdermal nicotine in doses comparable and double to those used for conventional smoking cessation treatment in humans does not adversely affect early patency of canine CABG up to 4 wk postoperatively. Transdermal nicotine, however, may increase production of and response to nitric oxide in bypass grafts.

show abstract

Section: Animalsmentioning

confidence: 99%